Clinical Wearable Biostrap Launches COVID-19 Study

Share Article

Biostrap partners with medical professionals to begin remote monitoring on COVID-19 patients and invites its users to donate their data for research purposes

Biostrap is launching a COVID-19 study that aims to provide a deeper understanding of this novel virus, its early signs, symptoms and even potential long-term effects.

The clinical-grade wearable is inviting all of its users to participate in tracking how COVID-19 impacts human physiology and has partnered with medical professionals at the UCLA School of Medicine and Tulane University to best analyze that data. All participants’ data will be kept anonymous and confidential. Additionally, Biostrap is also donating up to 100 devices to track COVID-19 patients for the purpose of better understanding the progression of the virus.

“No other wearable I am aware of has the same level of informative detail enabling me to collect and dissect the clinical data than Biostrap,” says Dr. Nassir Marrouche, Professor of Medicine at Tulane University, noting that life during and after COVID-19 is going to be different than it was before; wearables and telemedicine are the inevitable reality of medicine.

Remote monitoring is an increasingly important aspect of managing the current health pandemic. Being the most advanced, science-based platform, Biostrap is on a mission to improve global health. Its clinically validated biometric measurements such as heart rate variability, heart rate, oxygen saturation and respiratory rate can be key to monitoring the early signs, progression and regression of COVID-19.

“We are observing significant multi-organ damage post-COVID-19,” Dr. Marrouche says. “The blast in inflammation associated with COVID-19 is leading to short- and long-term organ or system damage. We are working to quantify this damage, at least in the cardiovascular system.”

Biostrap captures high-fidelity, raw PPG (photoplethysmography) waveforms that allow for an in-depth analysis of one’s health. These waveforms are the same kind that doctors use to evaluate their patients’ heart health.

“There’s a lot of data that can be predictive from raw PPG data for example well before any symptoms develop,” says Sameer Sontakey, CEO and Founder of Biostrap. “Each biometric we measure is influenced to a degree by COVID-19.”

It can help understand the infected patient’s continuous biometric behavior, including heart rate, heart rate variability, blood oxygen saturation, sleep patterns and respiratory rate.

“The raw PPG waveform provides tremendous clinical value,” says Dr. Marrouche, adding that “we can apply analysis of PPG to predict severe clinical outcomes like strokes, heart failure or hospitalizations. Also, PPG analysis would help early detect or even prevent disease.”

“We want to use the data we’re collecting in a way that’s meaningful,” says Sontakey. “Biostrap is a science-based platform, so let’s use the platform for good and allow people to work with us in a research capacity.”

About Biostrap
Biostrap is a science-driven platform developed to improve and optimize human health. Gathering data through their clinically validated wrist-worn device, Biostrap utilizes machine learning to provide actionable data to improve sleep, recovery and performance. In addition to providing an individualized approach to consumers via their app and web dashboard, Biostrap also delivers remote monitoring resources for medical and fitness professionals; as well as clinical researchers.

Biostrap measures heart rate variability, heart rate, respiratory rate, blood oxygen saturation, sleep stages and more than 100 activities and exercises. With the addition of external heart rate monitors, the Biostrap app captures real-time heart rate and heart rate variability, while the shoe pod can track gait, cadence, repetitions and velocity.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Klaudia Balogh
Visit website